Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 185Neoplasms 178Carcinoma, Non-Small-Cell Lung 162Prostatic Neoplasms 114Colorectal Neoplasms 111Lung Neoplasms 94Ovarian Neoplasms 85Neoplasm Metastasis 80Multiple Myeloma 75Pancreatic Neoplasms 73Leukemia, Myeloid, Acute 68Endometrial Neoplasms 53Stomach Neoplasms 49Squamous Cell Carcinoma of Head and Neck 48Melanoma 48Lymphoma 46Glioblastoma 45Recurrence 44Carcinoma, Renal Cell 44Urinary Bladder Neoplasms 42Carcinoma, Hepatocellular 41Brain Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Sarcoma 38Lymphoma, Non-Hodgkin 36Leukemia, Lymphocytic, Chronic, B-Cell 36Glioma 36Hematologic Neoplasms 35Small Cell Lung Carcinoma 34Esophageal Neoplasms 33

Interventions

enzalutamide 2inavolisib 1abiraterone 1PF06821497 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-Resistant Prostate Cancer × 30 days × Clear all
NCT06629779 2026-06-05

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting
900 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07287150 2026-06-04

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡